FR2722411B1 - IMMUNONANOPARTICLES COATED WITH ANTI-BETA2 MICROGLOBULIN MONOCLONAL ANTIBODIES AND THEIR USE FOR PROPHYLAXIS AND / OR THE TREATMENT OF PATHOLOGIES DUE TO HIV VIRUS INFECTION - Google Patents
IMMUNONANOPARTICLES COATED WITH ANTI-BETA2 MICROGLOBULIN MONOCLONAL ANTIBODIES AND THEIR USE FOR PROPHYLAXIS AND / OR THE TREATMENT OF PATHOLOGIES DUE TO HIV VIRUS INFECTIONInfo
- Publication number
- FR2722411B1 FR2722411B1 FR9408852A FR9408852A FR2722411B1 FR 2722411 B1 FR2722411 B1 FR 2722411B1 FR 9408852 A FR9408852 A FR 9408852A FR 9408852 A FR9408852 A FR 9408852A FR 2722411 B1 FR2722411 B1 FR 2722411B1
- Authority
- FR
- France
- Prior art keywords
- immunonanoparticles
- prophylaxis
- coated
- treatment
- monoclonal antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6933—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Biomedical Technology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Optics & Photonics (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9408852A FR2722411B1 (en) | 1994-07-18 | 1994-07-18 | IMMUNONANOPARTICLES COATED WITH ANTI-BETA2 MICROGLOBULIN MONOCLONAL ANTIBODIES AND THEIR USE FOR PROPHYLAXIS AND / OR THE TREATMENT OF PATHOLOGIES DUE TO HIV VIRUS INFECTION |
PCT/FR1995/000960 WO1996002278A1 (en) | 1994-07-18 | 1995-07-18 | Immunonanoparticles coated with anti-beta-2 microglobulin monoclonal antibodies |
AU30798/95A AU3079895A (en) | 1994-07-18 | 1995-07-18 | Immunonanoparticles coated with anti-beta-2 microglobulin monoclonal antibodies |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9408852A FR2722411B1 (en) | 1994-07-18 | 1994-07-18 | IMMUNONANOPARTICLES COATED WITH ANTI-BETA2 MICROGLOBULIN MONOCLONAL ANTIBODIES AND THEIR USE FOR PROPHYLAXIS AND / OR THE TREATMENT OF PATHOLOGIES DUE TO HIV VIRUS INFECTION |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2722411A1 FR2722411A1 (en) | 1996-01-19 |
FR2722411B1 true FR2722411B1 (en) | 1996-10-04 |
Family
ID=9465475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR9408852A Expired - Fee Related FR2722411B1 (en) | 1994-07-18 | 1994-07-18 | IMMUNONANOPARTICLES COATED WITH ANTI-BETA2 MICROGLOBULIN MONOCLONAL ANTIBODIES AND THEIR USE FOR PROPHYLAXIS AND / OR THE TREATMENT OF PATHOLOGIES DUE TO HIV VIRUS INFECTION |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU3079895A (en) |
FR (1) | FR2722411B1 (en) |
WO (1) | WO1996002278A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6750298B1 (en) * | 1998-01-29 | 2004-06-15 | Virsol | Surfactant copolymers based on methylidene malonate |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2755136B1 (en) * | 1996-10-25 | 1999-01-22 | Virsol | PROCESS FOR THE PREPARATION OF METHYLIDENE MALONATE NANOPARTICLES, NANOPARTICLES CONTAINING ONE OR MORE BIOLOGICALLY ACTIVE MOLECULES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
FR2789314B1 (en) * | 1999-02-09 | 2001-04-27 | Virsol | WOUND SUTURE MATERIAL BASED ON METHYLIDENE MALONATE |
AU2016265948B2 (en) | 2015-05-18 | 2018-12-06 | Alkahest, Inc. | Methods and compositions for treating aging-associated impairments |
CN109666072B (en) * | 2018-12-28 | 2022-04-05 | 江苏众红生物工程创药研究院有限公司 | Anti-human beta2-microglobulin antibodies and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4264766A (en) * | 1877-09-19 | 1981-04-28 | Hoffmann-La Roche Inc. | Immunological diagnostic reagents |
JPH06504274A (en) * | 1991-01-07 | 1994-05-19 | シンジェニックス・リミテッド | fine particles |
AU6681494A (en) * | 1993-04-22 | 1994-11-08 | Institut National De La Sante Et De La Recherche Medicale | Immunoparticles bearing monoclonal anti-cd4 antibodies and utilisation thereof |
-
1994
- 1994-07-18 FR FR9408852A patent/FR2722411B1/en not_active Expired - Fee Related
-
1995
- 1995-07-18 AU AU30798/95A patent/AU3079895A/en not_active Abandoned
- 1995-07-18 WO PCT/FR1995/000960 patent/WO1996002278A1/en active Application Filing
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6750298B1 (en) * | 1998-01-29 | 2004-06-15 | Virsol | Surfactant copolymers based on methylidene malonate |
Also Published As
Publication number | Publication date |
---|---|
WO1996002278A1 (en) | 1996-02-01 |
AU3079895A (en) | 1996-02-16 |
FR2722411A1 (en) | 1996-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
OA09498A (en) | "Use of baclofen for obtaining medicaments intended for the treatment of angina pectoris". | |
BE851328A (en) | COMPOSITION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | |
MA19428A1 (en) | Orthopedic support and support vest for the treatment of trauma and operations on the shoulder, shoulder girdle and upper limb | |
DZ1877A1 (en) | Dosage form of azithromycin for the treatment of microbial infections. | |
KR890002547A (en) | Monoclonal antibodies and peptides for the treatment and diagnosis of HIV infection | |
DZ1334A1 (en) | Use of a composition for the surface treatment of floors. | |
FR2684554B1 (en) | MEDICINES FOR THE TREATMENT OF INFLAMMATORY CONDITIONS OR FOR ANALGESIA. | |
FR2751658B1 (en) | USE OF A LIGAND CHEMOKINE (SDF-1) FOR LESTR / FUSIN / CXCR4 RECEPTOR TO PREVENT OR TREAT INFECTION WITH HIV-LIKE VIRUSES | |
FR2722411B1 (en) | IMMUNONANOPARTICLES COATED WITH ANTI-BETA2 MICROGLOBULIN MONOCLONAL ANTIBODIES AND THEIR USE FOR PROPHYLAXIS AND / OR THE TREATMENT OF PATHOLOGIES DUE TO HIV VIRUS INFECTION | |
FI944561A0 (en) | HIV-neutralizing recombinant human monoclonal antibodies for the prevention and treatment of HIV infection | |
FR2693129B1 (en) | Tools for the electrochemical treatment of the internal surface of a tube. | |
FR2758465B1 (en) | COMPOSITION FOR THE TREATMENT OF ASBESTOS | |
FR2340737A1 (en) | COMPOSITION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | |
FR2704227B1 (en) | IMMUNONANOPARTICLES CARRIING MONOCLONAL ANTI-CD4 ANTIBODIES AND THEIR USE FOR PROPHYLAXIS AND / OR THE TREATMENT OF CONDITIONS DUE TO HIV VIRUS INFECTION. | |
FR2737110B1 (en) | USE OF MONOCARBOXYLIC ACIDS FOR THE TREATMENT OF KERATINIC MATERIALS | |
FR2718024B1 (en) | Medicine and pharmaceutical composition for the treatment of inflammation. | |
FR2728161B1 (en) | ORTHESIS DEVICE FOR THE TREATMENT OF HALLUX VALGUS | |
FR2636229B1 (en) | ELBOW SUPPORT FOR THE TREATMENT OF EPICONDYLITIS AND EPITROCHLEITIS | |
OA06284A (en) | Process for the preparation of compositions for the treatment of chronic infections of trypanosomiasis. | |
BE894228A (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ATHEROSCLEROSIS | |
EP0655919A4 (en) | TREATMENT OF VIRAL INFECTIONS IN MAN. | |
FR2537710B1 (en) | INPUT STRUCTURE FOR ROTARY DRUMS FOR THE HEAT TREATMENT OF MATERIALS | |
FR2578425B1 (en) | IMMUNOGLOBULIN PREPARATIONS HAVING HIGH TITLES OF ANTI-ALLERGENIC BLOCKING ANTIBODIES, THEIR PREPARATION AND THEIR APPLICATIONS FOR THE TREATMENT OF ALLERGIES | |
FR2686246B3 (en) | WRIST ORTHOSIS FOR THE TREATMENT OF EPICONDYLALGIA. | |
FR2713087B1 (en) | Use of selegiline and its derivatives for the preparation of a medicament intended for the treatment of psoriasis. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ST | Notification of lapse |